Literature DB >> 27811938

Bone: Romosozumab - getting there but not quite yet.

Socrates E Papapoulos1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27811938     DOI： 10.1038/nrendo.2016.179

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  8 in total

1.  A Crisis in the Treatment of Osteoporosis.

Authors:  Sundeep Khosla; Elizabeth Shane
Journal:  J Bone Miner Res       Date:  2016-06-28       Impact factor: 6.741

2.  Romosozumab Treatment in Postmenopausal Women with Osteoporosis.

Authors:  Felicia Cosman; Daria B Crittenden; Jonathan D Adachi; Neil Binkley; Edward Czerwinski; Serge Ferrari; Lorenz C Hofbauer; Edith Lau; E Michael Lewiecki; Akimitsu Miyauchi; Cristiano A F Zerbini; Cassandra E Milmont; Li Chen; Judy Maddox; Paul D Meisner; Cesar Libanati; Andreas Grauer
Journal:  N Engl J Med       Date:  2016-09-18       Impact factor: 91.245

3.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Authors:  S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller
Journal:  JAMA       Date:  1999-10-13       Impact factor: 56.272

Review 4.  WNT signaling in bone homeostasis and disease: from human mutations to treatments.

Authors:  Roland Baron; Michaela Kneissel
Journal:  Nat Med       Date:  2013-02-06       Impact factor: 53.440

5.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

6.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Authors:  Steven R Cummings; Javier San Martin; Michael R McClung; Ethel S Siris; Richard Eastell; Ian R Reid; Pierre Delmas; Holly B Zoog; Matt Austin; Andrea Wang; Stepan Kutilek; Silvano Adami; Jose Zanchetta; Cesar Libanati; Suresh Siddhanti; Claus Christiansen
Journal:  N Engl J Med       Date:  2009-08-11       Impact factor: 91.245

7.  Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.

Authors:  H G Bone; D W Dempster; J A Eisman; S L Greenspan; M R McClung; T Nakamura; S Papapoulos; W J Shih; A Rybak-Feiglin; A C Santora; N Verbruggen; A T Leung; A Lombardi
Journal:  Osteoporos Int       Date:  2014-11-29       Impact factor: 4.507

Review 8.  Sclerostin Inhibition in the Management of Osteoporosis.

Authors:  Natasha M Appelman-Dijkstra; Socrates E Papapoulos
Journal:  Calcif Tissue Int       Date:  2016-03-26       Impact factor: 4.333
  8 in total
  1 in total

1.  Unmasking romosozumab.

Authors:  C E Uzoigwe; R Thimmaiah; A Eldessouky
Journal:  Osteoporos Int       Date:  2017-02-17       Impact factor: 4.507
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.